新一代肌钙蛋白T试验能一小时快速诊断心肌梗死(TRAPID-AMI 研究)

2016-01-24 MedSci MedSci原创

瑞士制药巨头罗氏(Roche)近日宣布,有关肌钙蛋白T检测试剂盒(Elecsys hs-cTnT)一小时快速诊断心脏病发作的前瞻性TRAPID-AMI1临床研究数据已在线发表于《急救医学年鉴》(Annals of Emergency Medicine)。该研究结果证实了一种新的方法,能够在急性胸痛患者中更快速地诊断心脏病发作。该策略是基于罗氏开发的心肌肌钙蛋白T高敏检测试剂盒,能够


瑞士制药巨头罗氏(Roche)近日宣布,有关肌钙蛋白T检测试剂盒(Elecsys hs-cTnT)一小时快速诊断心脏病发作的前瞻性TRAPID-AMI1临床研究数据已在线发表于《急救医学年鉴》(Annals of Emergency Medicine)(相关报道:ESC 2014:高敏cTnT可在1小时内排查急性心梗患者(TRAPID-AMI试验))。该研究结果证实了一种新的方法,能够在急性胸痛患者中更快速地诊断心脏病发作。该策略是基于罗氏开发的心肌肌钙蛋白T高敏检测试剂盒,能够将临床纳入(rule in)或排除(rule out)所需的观察时间由3-6小时缩短至1个小时。在临床治疗上,快速且可信的心脏发作诊断非常关键,因为从症状发作到治疗每推迟一个小时都会大幅增加患者死亡的风险。

该研究的首席研究员、瑞士伯尔尼大学心脏学教授Christian Mueller教授表示,由于这种新的方法,我们现在能够缩短急诊室急性胸痛患者诊断心脏病发作所需的时间。患者不再需要在急诊科等待3小时或更长的时间,而不知道其是否发生了一种急性的危及生命的疾病(心脏病发作),或者其胸痛是由其他原因引起。

心脏病发作(heart attack)或急性心肌梗死(AMI)是一种常见的心脏事件,这是由于供应至心脏肌肉区域的血液被中断,导致肌肉细胞逐渐死亡。心脏病发作后进行及时的治疗至关重要,因为每延迟30分钟,相对死亡风险将提高7.5%。据估计,伴有胸痛及其他症状考虑为AMI的患者,大约占急救室就诊病例的10-20%。在美国,大约每隔43秒,就有一人发生心脏病发作。

肌钙蛋白(troponin)是一种心脏肌肉蛋白,在心脏病发作期间被释放至血液中。早期的血液检测存在一定的限制因素,即检测肌钙蛋白释放所需的时间较长,有时甚至需要6个小时,而且灵敏度较低。在心脏病发作数小时内患者的死亡率最高。因此,及早地快速诊断并启动治疗,对患者的预后有很大的影响,并有可能挽救生命。

2015年8月在英国伦敦举行的欧洲心脏学会年度会议上通过了这一快速诊断的概念。其最新版的临床实践指南(2015 ESC NSTEM)支持已在TRAPID-AMI研究中得到验证的高灵敏度肌钙蛋白检测1小时诊断算法。罗氏诊断首席运营官Roland Diggelman表示,TRAPID-AMI研究的结果再次展现诊断是如何影响临床实践,并为改善患者预后做出贡献。

TRAPID-AMI1临床研究由罗氏开展的一项前瞻性观察研究,调查了2011-2014年超过1200例伴有急性胸痛的患者。该研究在三大洲、9个国家、12个研究机构开展。该研究是验证一种简便诊断程序的首个临床研究,从早期胸痛患者(从患者进入医院,疼痛发作最长6个小时)间隔一个小时采集的2份血液样品开展诊断。

TRAPID-AMI研究结果表明,这种新的诊断程序,能够将心脏病发作的确诊时间从3个小时或以上缩短至1个小时,使得医护人员能够更早地根据新指南(2015 ESC指南:非ST段抬高急性冠状动脉综合征患者管理)所推荐的对大多数患者进行治疗。

肌钙蛋白T高敏(cTnT-hs)试剂盒:

罗氏开发的Elecsys肌钙蛋白T高灵敏(cTnT-hs)试剂盒用于检测心肌肌钙蛋白(cardiac troponin),这是临床实践中诊断心脏病发作的首选生物标志物。目前,肌钙蛋白T检测结合心电图(ECG),已成为诊断心脏病发作的金标准。

罗氏cTnT-hs试剂盒的高灵敏度结合ECG,将显着加快“纳入(rule in)”或“排除(rule out)”决策制定,从而最大限度地提高有效治疗的可能性。同时,更快的决策可能有助于更好地管理急诊室的工作量及相关的医疗系统支出。

原始出处:

Mueller C, Giannitsis E, Christ M, Ordóñez-Llanos J, deFilippi C, McCord J, Body R, Panteghini M, Jernberg T, Plebani M, Verschuren F, French J, Christenson R, Weiser S, Bendig G, Dilba P, Lindahl B; TRAPID-AMI Investigators.Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med. 2016 Jan 8. pii: S0196-0644(15)01501-2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-10-24 xue8602
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 李继凯

    好东西

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 李继凯

    期待临床应用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 mingliqinmian

    我仔细看看

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这是个好消息!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1656690, encodeId=8d87165669081, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Jan 27 20:24:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105877, encodeId=b8fa1058e7bd, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005368, encodeId=db822005368de, content=<a href='/topic/show?id=1b141e76998' target=_blank style='color:#2F92EE;'>#TRAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17769, encryptionId=1b141e76998, topicName=TRAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Oct 24 20:24:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61544, encodeId=110e61544ba, content=好东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61545, encodeId=f0086154571, content=期待临床应用, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 23:37:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60436, encodeId=8dea6043679, content=我仔细看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e471683900, createdName=mingliqinmian, createdTime=Wed Jan 27 09:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59904, encodeId=a1e55990400, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59905, encodeId=9f8b599057d, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:09:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59523, encodeId=2ed159523af, content=这是个好消息!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 14:49:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569112, encodeId=0a3d156911232, content=<a href='/topic/show?id=2651810889c' target=_blank style='color:#2F92EE;'>#肌钙蛋白T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81088, encryptionId=2651810889c, topicName=肌钙蛋白T)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f7f15492758, createdName=huangdf, createdTime=Tue Jan 26 02:24:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]

相关资讯

Hypertension:慢性肾病患者难治性高血压的发生率较高,预后不好

慢性肾脏病患者中难治性高血压(ATRH)和临床结果的关系尚未研究清楚。研究者分析慢性肾功能不全队列研究(CRIC)中3367名高血压患者的数据,确定非透析慢性肾病患者ATRH的发生率,相关性及临床预后。ATRH的定义为应用三种及三种以上的抗高血压药血压≥140/90mmHg,或者基线时,应用四种及四种以上的抗高血压的药,才能维持血压在目标值。ATRH的发生率为40.4%。高龄,男性,黑人,糖尿病,

NEJM:经皮置猪尾巴导管治疗肺栓塞-案例报道

http://www.nejm.org/doi/full/10.1056/NEJMicm1415847

Mayo Clin Proc:美国老年人带状疱疹发生后,心肌梗死和卒中发生风险增加

目的:旨在评估美国社区老年人群中带状疱疹后,卒中和心肌梗死(MI)发生的风险。病人和方法:研究者进行了一项社区队列研究(1986年1月1日至2011年10月1日)比较明尼苏达奥姆斯特德县50岁及以上的有无带状疱疹的居民,和按照性别和年龄相匹配的无带状疱疹史的受试者卒中和MI发生的风险。指标性带状疱疹后3、6、12、36个月后加为长期风险的危险比(长达28.6年)来表示心肌梗死和中风的OR值。结果:

JACC:DTBT时间越短,心梗患者预后越好!

DTBT时间是患者在院外出现心脏病发作至抵达急诊室经皮冠状动脉介入并恢复血液流动之间的时间。 根据美国心脏协会的描述了,SI段抬高型心肌梗死(STEMI)是一种严重的心脏病,并导致心脏血流受阻而使心脏大面积受损。美国心脏病协会建议(ACC),STEMI患者应该在入院90分钟内行经皮冠状动脉介入治疗。 约90%的患者经皮冠状动脉介入术后,心脏表面血流恢复,但约1/3的患者心肌血流量未恢复。这项研究的

Diabetes Obes Metab:不同胰岛素治疗的2型糖尿病患者急性心梗风险比较

研究者对2型糖尿病患者进行了一项研究,根据胰岛素使用种类将其分组,比较不同组患者的急性心肌梗死(AMI)风险。该研究就2004-2009年间德国保险数据,对2型糖尿病患者进行了一项回顾性队列研究。共涉及了21 501名新的胰岛素使用者。研究数据显示,使用预混胰岛素治疗的患者年龄大于胰岛素类似物或NPH胰岛素治疗患者(平均年龄 70.7 vs. 64.1和61.6岁),且预混胰岛素使用者并存病更多。

Circulation:牙周炎增加了患心肌梗死的风险

牙周炎(PD)和心血管疾病(CVD)之间的关系一直存在争议。PD是CVD患者常见的现象。据推测,PD可能与心血管疾病的风险有关,研究人员在PAROKRANK中测试了这个假设。在805名第一次患MI的患者(年龄<75岁)和805名年龄(平均62±8岁),性别(男性81%)和地域匹配的无MI对照群组中,研究人员对其进行标准化牙科检查包括全景x射线。牙周状况被定义为健康(≥80%的剩余骨)或轻度或